Pfizer/Mylan: Pending Clash Of Quality Systems Could Determine Fate Of New Firm
Executive Summary
After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?
You may also be interested in...
FDA Warning Letter Blasts Mylan’s Lax API Impurity Controls
Concerned about another possible nitrosamine scare, the US FDA has sent a warning letter to Mylan focusing on the firm’s failure to control contamination risks of its APIs and inadequate testing of reused solvents.
FDA Warning Letter Blasts Mylan’s Continued Lax Impurity Controls for APIs
Concerned about another possible nitrosamine scare, US FDA warning letter to Mylan focuses on firm’s failure to control contamination risks of its APIs and its inadequate testing of reused solvents.
Mylan/Biocon Running Out Of Time To Get Insulin Approved Before US Transition
After second complete response letter, Mylan and Biocon have just over six months to resolve manufacturing issues and obtain full approval or face having to resubmit the insulin as a biologics license application.